Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -18.86% is 65% below its 5-year average of -11.41%, near the low end of its 5-year range (-18.86%–-1.09%).
45.52% below its 12-month average of -12.96%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.83%.
RETURN ON ASSETS (ROA)
-18.86%
RETURN ON ASSETS (ROA) AVG TTM
-12.96%
RETURN ON ASSETS (ROA) AVG 3Y
-12.20%
RETURN ON ASSETS (ROA) AVG 5Y
-11.41%
RETURN ON ASSETS (ROA) AVG 10Y
-5.96%
RETURN ON ASSETS (ROA) AVG 15Y
-8.51%
RETURN ON ASSETS (ROA) AVG 20Y
-7.51%
CURRENT VS TTM AVG
-45.52%
CURRENT VS 3Y AVG
-54.56%
CURRENT VS 5Y AVG
-65.22%
CURRENT VS 10Y AVG
-216.59%
CURRENT VS 15Y AVG
-121.62%
CURRENT VS 20Y AVG
-151.03%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+41.55%
vs the sector median at left
Ionis Pharmaceuticals, Inc.
Market Cap
$7.31B
Return on Assets (ROA)
-18.86%
TTM Avg
-12.96%
3Y Avg
-12.20%
5Y Avg
-11.41%
Market Cap
$7.61B
Return on Assets (ROA)
13.18%
TTM Avg
-36.35%
3Y Avg
-30.02%
5Y Avg
-30.02%
Market Cap
$7.61B
Return on Assets (ROA)
7.23%
TTM Avg
4.54%
3Y Avg
2.50%
5Y Avg
1.48%
Market Cap
$7.63B
Return on Assets (ROA)
-46.45%
TTM Avg
-48.58%
3Y Avg
-49.83%
5Y Avg
-41.46%
Market Cap
$6.99B
Return on Assets (ROA)
1.51%
TTM Avg
13.71%
3Y Avg
9.00%
5Y Avg
4.65%
Market Cap
$7.76B
Return on Assets (ROA)
8.55%
TTM Avg
-64.90%
3Y Avg
-64.30%
5Y Avg
-51.23%
Market Cap
$7.81B
Return on Assets (ROA)
-24.40%
TTM Avg
-35.09%
3Y Avg
-99.06%
5Y Avg
-78.95%
Market Cap
$6.66B
Return on Assets (ROA)
17.41%
TTM Avg
17.14%
3Y Avg
16.98%
5Y Avg
18.36%
Market Cap
$7.99B
Return on Assets (ROA)
26.93%
TTM Avg
23.05%
3Y Avg
-16.42%
5Y Avg
-33.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. (IONS) | $7.31B | -18.86% | -12.96% | -12.20% | -11.41% |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 13.18% | -36.35% | -30.02% | -30.02% |
| HealthEquity, Inc. (HQY)vs › | $7.61B | 7.23% | 4.54% | 2.50% | 1.48% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | -46.45% | -48.58% | -49.83% | -41.46% |
| Alkermes plc (ALKS)vs › | $6.99B | 1.51% | 13.71% | 9.00% | 4.65% |
| Caris Life Sciences, Inc. (CAI)vs › | $7.76B | 8.55% | -64.90% | -64.30% | -51.23% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | -24.40% | -35.09% | -99.06% | -78.95% |
| Chemed Corporation (CHE)vs › | $6.66B | 17.41% | 17.14% | 16.98% | 18.36% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 26.93% | 23.05% | -16.42% | -33.67% |
| Immunovant, Inc. (IMVT)vs › | $6.63B | -63.13% | -53.05% | -49.25% | -42.24% |
ROA
-18.9%
ROE
-128.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -10.81% |
| 2024-12-31 | -15.11% |
| 2023-12-31 | -12.25% |
| 2022-12-31 | -10.64% |
| 2021-12-31 | -1.09% |
| 2020-12-31 | -18.59% |
| 2019-12-31 | 8.60% |
| 2018-12-31 | 10.26% |
| 2017-12-31 | 0.03% |
| 2016-12-31 | -6.62% |
| 2015-12-31 | -9.31% |
| 2014-12-31 | -4.08% |
| 2013-12-31 | -7.16% |
| 2012-12-31 | -12.00% |
| 2011-12-31 | -17.49% |
| 2010-12-31 | -11.13% |
| 2009-12-31 | 23.60% |
| 2008-12-31 | -3.17% |
| 2007-12-31 | -4.25% |
| 2006-12-31 | -17.94% |
| 2005-12-31 | -43.52% |
| 2004-12-31 | -68.37% |
| 2003-12-31 | -28.36% |
| 2002-12-31 | -16.47% |
| 2001-12-31 | -17.70% |
| 2000-12-31 | -29.19% |
| 1999-12-31 | -57.42% |
| 1998-12-31 | -44.75% |
| 1997-12-31 | -26.38% |
| 1996-12-31 | -26.16% |
